Back to search results

Remote Ischemic Preconditioning for Heart and Kidney Protection in Heart Failure

This study is testing a treatment called remote ischemic preconditioning (RIPC) to see if it can protect your kidneys and heart. RIPC involves inflating a blood pressure cuff on your arm or leg for short periods. We are studying if RIPC can prevent acute kidney injury (sudden kidney damage) in people with heart failure who are having a heart procedure (coronary angiography and/or PCI). You might be able to join if you are 18 or older, have heart failure with a reduced pumping ability, and are scheduled for one of these heart procedures. The main goal is to see if RIPC reduces kidney injury 24 and 48 hours after the procedure. The study status is currently unclear.

Study design
This is a double-blind, sham-controlled study, meaning neither you nor your doctors will know if you are receiving the active treatment or a non-active control. About 240 people are expected to participate.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will look at kidney function at 24 and 48 hours, and other outcomes like functional capacity at one month and major adverse kidney events at three months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04982419

Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial

Recruiting
PHASE2Ages 18+InterventionalPrevention
VA Office of Research and Development
~240 participants
Updated 2025-12-15 on ClinicalTrials.gov
What's tested:Remote ischemic preconditioningSham remote ischemic conditioning

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Contrast-associated acute kidney injury
Measured over 24 and 48 hours time points

Conditions

Acute Kidney Injury
Heart Failure
Contrast Induced Nephropathy
Coronary Angiography
Percutaneous Coronary Intervention

Explore related trials

Acute Coronary SyndromeCoronary Artery DiseaseHeart Failure

Where it's being run

3 sites across 3 states
Pennsylvania1
Texas1
Virginia1

Study leadership

  • Oladipupo Olafiranye, MD MS · PRINCIPAL_INVESTIGATOR · VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX

Who to contact

Oladipupo Olafiranye, MD MS
[email protected]
(214) 857-2923
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years
Diagnosis of heart failure with reduced LVEF \<50%
Pre-procedure intravenous normal saline fluid restriction status
Society for Cardiovascular Angiography and Interventions (SCAI) AKI risk score (\>1%)
Referral for coronary angiogram and/or PCI
Suspected stable coronary artery disease or acute coronary syndrome

Exclusion

Inability to give informed consent
Unstable BP (SBP \> 200 or \<80 mmHg) at the time of enrolment
Upper limb peripheral arterial disease
Unavailability of at least one arm for RIPC/Sham-RIPC application
Kidney transplant
Renal disease requiring dialysis
Prior exposure to contrast media within 72hrs preceding coronary angiography
Pregnancy
Prisoner

What this trial measures

  • Contrast-associated acute kidney injury24 and 48 hours time points

    The investigators define contrast-associated acute kidney injury as a relative increase in serum creatinine of 0.3mg/dl compared with initial creatinine at 48 hours time point after coronary angiography and/or PCI. The will obtain levels of serum creatinine at baseline, then at 24 and 48 hours time points.